Press Release Highlights: – EPI-321 is the first investigational therapy designed to silence DUX4 expression via epigenetic modulation – FDA has granted Fast Track, Rare Pediatric Disease, and Orphan Drug … Continue reading Epicrispr Biotechnologies Doses First Patient in First-in-Human Clinical Trial of EPI-321 for Facioscapulohumeral Muscular Dystrophy